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Abstract 
Total body bone absorptiometry reveals low mineral 
density in both postmenopausal osteoporosis and osteo-
malacia patients. The method was used to investigate 
the effect of calcitriol administration on patients suffer-
ing from one of these conditions. In osteomalacia, the 
administration of calcitriol resulted in a dramatic 
improvement in bone mineral density (sometimes up to 
50% in 12 months), indicating the rapid mineralization 
of previously uncalcified bone tissue as a result of the 
normalization of the Ca x P product. In osteoporosis a 
similar treatment was seen to halt the progressive de-
crease in bone mineral levels and sometimes resulted in 
minor increases in density (up to 5%). This is likely to 
be due to a normalization of intestinal calcium mal-
absorption which halts secondary homeostatic bone 
resorption. 
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Introduction 
Osteomalacia and postmenopausal osteoporosis are 
two pathological conditions that are very different in 
terms of their etiology, physiopathology and morbid 
anatomy. In osteomalacia, the bone mass normally 
produced by osteoblasts remains incompletely calcified 
mainly because of hypophosphatemia (due to insufficient 
intestinal absorption and/or the excessive renal loss of 
phosphate), which lowers the Ca x P product to below 
the minimum limit necessary for the formation of hy-
droxyapatite and the nucleation of its crystals in the or-
ganic matrix of newly formed bone. In postmenopausal 
osteoporosis, bone mass decreases mainly as a result of 
the increase in bone resorption, which occurs to main-
tain calcium homeostasis. 
The possibility of measuring bone mineral content 
in vivo has always been a primary objective in the study 
of calcium and phosphate metabolism, but traditional 
radiology provides approximate indications concerning 
mineralization only when the skeleton has lost at least 
30-40% of its mineral content. The introduction of 
absorptiometry (bone densitometry) has given a consid-
erable boost to mineralometric research and the spread 
of such measurements to practical diagnostics. 
Single photon absorptiometry [2] of the wrist has 
been very useful in screening large numbers of people at 
risk for osteoporosis, but it is difficult to use in longitu-
dinal studies because of serious problems in positioning 
and repositioning the explored bone segment, which may 
surreptitiously modify bone mineral density measure-
ments. Dual-photon absorptiometry [37] offers impor-
tant methodological advantages: (a) dual-photon absorp-
tiometry (DPA) uses gadolinium 153, a radioisotope that 
emits two photons with two different energy levels ( 44 
and 100 KeV); (b) dual-energy X-ray absorptiometry 
(DPX or DEXA) uses an X-ray source with a cathode 
tube alternately emitting X-rays of70 and 140 keV [23]. 
X-ray mineral measurements provide a higher photon 
flux which allows greater precision, a reduction in the 
duration of the examination, and a cheaper and longer 
lasting source. 
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Figure 1. Biopsy of the 
iliac crest in a case of 
postmenopausal osteo-
porosis (von Kossa stain 
on non-decalcified bone). 
The bone trabeculae are 
extremely thin with a 
widening of the medullary 
spaces; hardly any osteo-
blasts or osteoclasts can 
be seen. The black col-
our of the trabeculae 
show that these are com-
pletely calcified. Bar = 
200 ~tm. 
Table 1. Total body densitometry (DEXA) g/cm2 in Italians (normal values by decade). 
Age -+ 21-30 31-40 41-50 
Females 
Maximum 1.17 1.17 1.18 
Minimum 0.98 1.03 1.01 
Males 
Maximum 1.28 1.18 1.26 
Minimum 1.07 1.01 1.04 
In our opinion, dual-photon lumbar absorptiometry 
suffers from a number of drawbacks associated with 
anomalies in the anatomy of the explored region: prob-
lems in positioning and repositioning the lumbar spine 
when this is deformed by kyphosis or scoliosis; the un-
certain visualization of intervertebral spaces; vertebral 
crushing; the presence of osteophytes or bone bridges, 
etc., all of which are frequently encountered in the 
elderly for whom this technique otherwise would be par-
ticularly appropriate [29]. 
Consequently, although lumbar vertebrae mineral 
measurements are extremely useful for evaluating miner-
al content under normal conditions, or in diseases in-
volving osteopenia or demineralization, the prevailing 
tendency today is to use total body scans because they 
allow the drawbacks of the technique to be overcome 
and ensure impartial measurements. The prevalence of 
postmenopausal osteoporosis, which has been progres-
sively increasing in white women throughout the world, 
has made bone absorptiometry very popular in the diag-
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51-60 61-70 71-80 
1.13 1.09 1.08 
0.99 0.97 0.95 
1.19 1.24 1.13 
1.06 1.08 1.05 
nostics of this metabolic disease of the skeleton [4, 24, 
25]. 
The aim of the present study was to compare total 
body bone densitometry in postmenopausal osteoporosis 
and nutritional osteomalacia, two pathological conditions 
in which the positive therapeutic effect of calcitriol has 
been widely demonstrated. No consideration was given 
to other types of osteopenia. 
Materials and Methods 
The study included patients with osteomalacia or 
postmenopausal osteoporosis. All patients included in 
the study gave informed consent. The diagnoses of post-
menopausal osteoporosis and nutritional osteomalacia for 
this study were made on the basis of traditional clinical 
and radiological criteria: bone fractures and deforma-
tions; laboratory data, such as plasma calcium, phos-
phate and alkaline phosphatase levels, 24-hour urinary 
calcium, phosphate and hydroxyproline; radio-calcium 
. Calcitriol-treated osteoporosis and osteomalacia 
Figure 2. Biopsy of the 
iliac crest in a case of 
postmenopausal osteo-
porosis. The resorption 
of the cortex leads to a 
"spongy transformation" 
of cortical bone: no 
Haversian channels can be 
seen under the perios-
teum. Bar = 200 JLm. 
Figure 3. Biopsy of the 
iliac crest in a case of 
nutritional osteomalacia 
(von Kossa stain on non-
decalcified bone). The 
thickness of the bone 
trabeculae is normal. 
Trabeculae show areas of 
completely calcified bone 
(black) alternating with 
large red areas of non-
calcified osteoid tissue, 
which appear grey in the 
black and white photo-
graph. Bar = 200 JLm. 
oral tests to assess intestinal calcium transport. In most 
of the patients, the diagnosis was confirmed by a biopsy 
of the iliac crest. 
The mean age of the postmenopausal osteoporotic 
women at the start of treatment was 66 ± 9. 5 years 
(range 41 to 81); that of the osteomalacic women was 61 
± 12.6 years (range 34 to 78). 
No particular diet was prescribed. Our postmeno-
pausal osteoporotic patients were ambulatory and their 
diet was that of average elderly Italian women: bread, 
pasta or rice, vegetables, fruit, and very small quantities 
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of meat, cheese and milk. In brief, a diet that is much 
poorer in calcium than that of the populations of 
Northern Europe and the USA (500-700 mg/day Ca). 
The skeleton of the patients was analyzed by total 
body absorptiometry, which allows an accurate and pre-
cise analysis of the mineral content of the whole skele-
ton, as well as of some regions of interest. The Lunar 
DEXA densitometer used by us scans at a speed of 8 or 
16 em/sec with longitudinal step intervals of 1 em; the 
pixel size is 4.8 x 9.6 mm and, of the total number of 
22,000 pixels, 4500 correspond to bone. The radiation 
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Figure 4 (at left). Total body bone mineral density (g/cm2) in 136 women with postmenopausal osteoporosis. The 
absorptiometry values are below normal in all of the women (hatched area) (mean value 0.911). 
Figure 5 (at right). Total body bone mineral density (g/cm2) in 36 subjects with histologically proven osteoma1acia. 
The absorptiometry values are much lower than normal in all cases (hatched area) (mean value 0.804). The redu<Ction 
in absorptiometric values is particularly significant in the younger subjects 
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Figure 6. The behaviour of total 
body bone mineral density in 30 
women with postmenopausal o steo-
porosis treated for two years with 
an inert placebo (left panel) and in 
30 women with postmenopausal 
osteoporosis continuously tf'eated 
with calcitriol (1 J.'g/day) for two 
years (right panel). The progres-
sive reduction in bone mineral den-
sity (-5% ± 1.7 after two years) 
corresponding to progressive bone 
loss is clear in the placebo group 
and it is halted in the calcitriol 
group ( + 1.2 % ± 1.6). 
5 
4 
3 
2 
dose is about 1 mRem. The data supplied include: total 
body bone mineral content (TBBM) , of which calcium 
represents 3 8%, the total bone density (TBD), and the 
bone density of the areas of major interest (the spinal 
column for spongy bone; the limbs for compact bone) . 
The coefficient of variation (precision) of total bone 
density is 0.34% in normal subjects and 0.70% in 
osteoporotic patients [30]. 
The range of correlation between bone mineral den-
sity and age has been constructed for normal subjects of 
both sexes (see Table 1) [22, 26] . 
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Results 
Figures 1-3 describe the histology of postmenopaus-
al osteoporosis and osteomalacia. Postmenopausal osteo-
porosis is defined as bone loss, with normal mineraliza-
tion of the remaining bone. The bone trabeculae be-
come increasingly thinner, fracture and many of them 
disappear (Fig. 1). The resorption of the cortex leads to 
a progressive "spongy transformation" of cortical bone 
(Fig. 2) . In osteomalacia, on the other hand, the osteo-
blasts regularly produce the bone collagen that structures 
Calcitriol-treated osteoporosis and osteomalacia 
n. patients 
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Figure 7. The behaviour of 
total body bone mineral den-
sity in a group of women with 
postmenopausal osteoporosis 
continuously treated with 
calcitriol (1 p.g/day) for 
periods ranging from one to 
six years. The columns show 
the mean percentage modifica-
tions and standard deviation in 
the individual groups. The 
majority of the patients re-
mained within the precision 
limits of the method. In other 
words, calcitriol impeded the 
progressive bone loss which 
would have occurred if the pa-
tients had not been treated (or 
if they had been treated with 
placebo). 
0.01----
-0.5 
-1.0 
-1.5 
years of treatment 
the osteoid layers, but these remain incompletely calci-
fied (Fig. 3). 
In the study summarized in Figure 4, a total of 136 
postmenopausal osteoporotic women were involved. 
The values of total body absorptiometry were lower than 
in age-matched non-osteoporotic women (Fig. 4). The 
total body absorptiometry values of 36 patients with 
nutritional osteomalacia were also lower than those of 
age-matched normal subjects (Fig. 5). 
In a double-blind study, we compared 30 postmeno-
pausal osteoporotic women given 1 p.g/day of calcitriol 
with 30 age-matched postmenopausal osteoporotic wom-
en given an inert placebo. In the "untreated" placebo 
group, bone mineral density decreased, and a significant 
number of these patients voluntarily stopped the treat-
ment after one year probably because of its poor effica-
cy; in those who completed the two-year study, the aver-
age decrease in density was about 4-5% (Fig. 6, left 
panel). The bone density did not decrease in the group 
of postmenopausal osteoporotic patients treated with cal-
citriol. In some, but not all, women, bone mineral den-
sity actually increased. However, in any case, the loss 
of bone mineral density was halted (Fig. 6, right panel). 
This was also seen in a study ranging over 6 years in-
cluding 336 patients with postmenopausal osteoporosis 
(Fig. 7). Since the patients experienced a positive effect 
from the treatment, compliance was better than in the 
placebo group. 
In a group of patients with nutritional osteomalacia 
and total body densitometry values that were lower than 
normal, two years' treatment with calcitriol resulted in 
a dramatic increase in these values (Fig. 8), which 
sometimes increased by more than 50% after a period of 
143 
POSTMENOPAUSAL OSTEOPOROSIS 
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12-24 months. The three different panels of Figure 8 
summarize the effects of the treatment on total body 
bone absorptiometry: (a) in 30 patients with postmeno-
pausal osteoporosis given placebo; (b) in 30 patients 
with postmenopausal osteoporosis given 1 p.g/day of cal-
citriol; and (c) in 7 patients with nutritional osteomalacia 
given 1 p.g/day of calcitriol. 
Statistical comparisons of the densitometric percent 
variations after two years has been performed: (1) in 
placebo versus calcitriol treated osteoporotic patients 
(-5% ± 1.7versus 1.2% ± 1.6;p < 0.01); and(2)in 
osteoporotic versus osteomalacic patients given calcitriol 
(1.2% ± 1.6 versus 26% ± 10.6; p < 0.01 ). 
The data on osteomalacia patients included in the 
present papers have been collected over several years; 
therefore, it was not possible to perform a double blind 
trial of this serious disease; this was also not possible 
for ethical reasons. Nevertheless, the efficiency of vita-
min D and its metabolites in osteomalacia is largely 
known as well as the rapid worsening of the disease in 
unattended patients. 
In some of the patients with osteomalacia, the sub-
sequent visual display images of the densitometer were 
very impressive (Fig. 9), and it was possible to directly 
follow the progressive increase in bone mineral density 
throughout the course of treatment. 
Discussion 
With regard to bone mineral density, patients with 
osteomalacia have a different response to calcitriol 
treatment, compared to patients with postmenopausal 
osteoporosis. In patients with nutritional osteomalacia, 
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BMD OSTEOPOROSIS OSTEOPOROSIS 
( calcitriol ) 
OSTEOMALACIA Figure 8. The behaviour of 
total body bone mineral den-
sity in a number of subjects 
with nutritional osteomalacia 
given long-term calcitriol 1 
p,g/day treatment (right panel). 
The increase in absorptiometr-
ic values is constant and, in 
some case, has reached con-
siderable percentages (mean: 
26% ± 10.6 after two years). 
Response was greater in 
patients who had not pre-
viously received treatment 
with vitamin D or its metabo-
lites, and was much more evi-
dent than· in the osteoporotic 
patients treated with calcitriol 
(centre panel: 1.2% ± 1.6)) 
or placebo (left panel: -5% ± 
1. 7). The horizontal axis 
shows the number of years of 
treatment and the vertical axis 
the percent increases in bone 
mineral density; the triangles 
indicate the mean values. 
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calcitriol normalizes the intestinal absorption of calcium 
and phosphate, restores normal plasma calcium and 
phosphate levels and thus increases the Ca x P product. 
This restores the production and nucleation of hydroxy-
apatite crystals in newly formed bone and makes the 
transformation of osteoid tissue into normally calcified 
bone possible. Pain disappears, normal muscular activi-
ty is resumed, the Looser-Milkman pseudo-fractures re-
cover, and X-rays reveal recalcification of the skeleton. 
In women with postmenopausal osteoporosis, bone 
loss is due to a homeostatic mechanism with the purpose 
to maintain normal blood calcium levels. The need to 
make use of skeletal calcium may arise because the de-
crease in estrogen hormone levels negatively affects the 
renal hydroxylation of vitamin D to calcitriol (necessary 
to stimulate the physiological mechanism of intestinal 
calcium transport), and thus leads to a negative calcium 
balance. 
It is generally known that in postmenopausal osteo-
porosis, as in other generalized osteoporoses, total body 
densitometry reveals a decrease in bone mineral density 
related to the real "bone loss" underlying osteoporosis. 
The similar decrease in bone mineral density observed 
in osteomalacia cannot be accounted for by a. real de-
1 years 2 
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crease in "bone mass" and, in these patients, it is there-
fore incorrect to speak of "bone loss" because their bone 
mass is volumetrically normal, even though it is poorly 
mineralized. It is also generally known that the bone 
mineral density of untreated women with postmenopausal 
osteoporosis decreases by 4-5% every year. 
Since the studies by Albright and Reifenstein [1], it 
has been generally accepted that the most important step 
in the pathophysiology of postmenopausal osteoporosis 
is estrogen deficiency. Albright and Reifenstein [1] 
demonstrated that women with postmenopausal osteo-
porosis presented a negative calcium balance mainly be-
cause of fecal calcium losses, which disappeared when 
estrogens were administered and reappeared upon the 
withdrawal of these hormones. Our own studies in post-
menopausal osteoporotic women documented a decrease 
in the active intestinal transport of radioactive calcium 
[7]. These findings have since been confirmed by others 
[17, 33]. In a double-blind study comparing estrogens/ 
gestogens and placebo, we demonstrated that this combi-
nation of hormones corrected intestinal radio-calcium 
malabsorption in postmenopausal osteoporotic women 
[8]. 
The results described in the present study show, that 
Calcitriol-treated osteoporosis and osteomalacia 
Figure 9. Successive 
visual displays of total 
body absorptiometry in a 
patient with nutritional 
osteomalacia treated with 
calcitriol 1 /lg/day for 10 
months. It can be seen 
that the skeleton "re-
appears" as the treatment 
progresses. 
0 
by restoring calcium malabsorption, calcitriol opposes 
progressive bone resorption, and in a certain number of 
cases, it actually increases densitometric values. 
Since the discovery of the hydroxylated metabolites 
of vitamin D [13, 16], a number of authors have found 
a decrease in 1,25(0H)2vitD levels in postmenopausal 
osteoporosis [17, 20, 21]. We have previously demon-
strated that, in women with postmenopausal osteo-
porosis, the oral administration of calcitriol 
(1,25(0H)2vitD) at a physiological dose of 1 /lg/day 
normalizes the intestinal transport of radio-calcium in a 
period of ten days; the result was different when an 
equivalent dose of 24,25(0H)2vitD was given [27]. At 
this dose, oral calcitriol rapidly corrects intestinal 
calcium malabsorption, reestablishes a positive calcium 
balance, rapidly eliminates bone pain, and prevents new 
pathological fractures [9, 10, 12, 19, 33, 35]. This 
effect continues without interruption provided calcitriol 
is taken every day, as can be seen from the results in 
many of our patients, some of whom have been under 
observation for a period of up to 14 years. We did not 
observe adverse effects provided the patients were not 
given oral calcium supplementation; the long-term com-
pliance of the patients confirmed the efficacy of this 
treatment (relief of pain, well-being and no additional 
fractures). 
In postmenopausal osteoporosis, calcitriol is a "re-
placement therapy". Treatment with calcitriol is funda-
mentally different from vitamin D treatment. Both par-
ent vitamin D and calcidiol (250HvitD) are useless in 
the therapy of postmenopausal osteoporosis because, in 
this particular condition, the presence of a hydroxyl 
group in position 1 is necessary in order to obtain a pos-
itive effect on intestinal calcium absorption. This is 
confirmed by the efficacy of other 1a-hydroxylated me-
tabolites of vitamin D, such as 1,24(0H)2vitD [31] and 
,~!( .. · .,.~~ ·~; . .. : I.!~ 
.!.•(j.· , .\ , 
~: ' . ~ . . 
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1a-OHvitD [10, 11, 32]. The hypothesis that estrogens 
act directly on renal1a-hydroxylase has been supported 
by the studies of DeLuca, Castillo and Tanaka [13, 14, 
15], which had very appropriate experimental designs: 
e.g., hatching hens produce large quantities of estrogens 
and there is a parallel increase in the renal production of 
1a-hydroxylase; this was not the case with chicks or 
adult chickens unless they were given estrogens. Studies 
of this kind are not possible in women; nevertheless, a 
number of authors have stressed the positive effect of 
estrogens on 1,25(0H)2vitD levels, which leads to a 
parallel improvement in radio-calcium absorption [5, 17, 
18, 36], and the negative effects of ovariectomy in fer-
tile women [28]. Hence, the possibility that the renal 
hydroxylation of 250HvitD is the final step of this 
metabolic process, is a viable hypothesis. 
In osteomalacia, the availability of calcium and 
phosphate normalizes the low Ca x P product responsi-
ble for the incomplete calcification of osteoid tissue, and 
allows the tissue to undertake the formation and nuclea-
tion of hydroxyapatite crystals: densitometry faithfully 
records its extreme avidity for bone mineral. Radio-cal-
cium and 99mTc-methylene-diphosphonate kinetic stud-
ies have clearly shown the enlargement of the exchange-
able calcium pool in osteomalacia [6] and the high affini-
ty of osteoid-tissue for radioactive bone seeking tracers 
[3]. 
In osteoporosis, this does not occur. Under baseline 
conditions, there is a reduction in bone mass (hence the 
low densitometric values), but the bone is fully calcified 
and kinetic studies show that the uptake of tracers with 
affinity for bone is low. During calcitriol treatment, it 
is impossible to verify the mineralization of already 
completely calcified bone. Furthermore, a large produc-
tion of bone (large enough to result in an obvious irr-
crease in absorptiometric values over baseline levels) is 
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highly unlikely not only because of the small number of 
active osteoblasts [34], but also because the bone trabe-
culae occur at large distances from one another and the 
medullary spaces are increased. The production of new 
bone cannot take place inside these spaces, because bone 
production requires a template upon which the osteo-
blasts can deposit the organic layers of bone, and this 
cannot be guaranteed by the remaining sparse and thin 
trabeculae. 
Conclusions 
From the present study we conclude that the identi-
fication of osteoporosis simply on the basis of low den-
sitometric values may lead to a mistaken diagnosis: 
when bone mineral absorptiometry shows less than nor-
mal values, it is more correct to speak of "a reduction 
in bone mineral content", which may mean either real 
bone loss, or poor mineralization of a quantitatively 
normal bone mass. This distinction is anything but 
academic. 
In osteomalacia, the rapid increase in bone densi-
tometry values during calcitriol treatment indicates the 
rapid mineralization of a preexisting, quantitatively nor-
mal, but incompletely calcified bone mass, which quick-
ly recalcifies once the necessary physical and chemical 
conditions are created. In osteoporosis, on the other 
hand, the loss of bone mineral density is halted, and a 
possible slight increase in densitometry values (1-5% 
over baseline values), are sufficient to indicate the satis-
factory therapeutic activity of calcitriol. This activity 
does, however, not lead to the vigorous production of 
newly formed bone but mainly to the arrest of the home-
ostatic pathologic mechanism of bone hyper-resorption. 
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Discussion with Reviewers 
H. U. Bryant: The authors seem to be arguing that the 
entire basis for post-menopausal bone loss is due to vita-
minD abnormalities associated with estrogen deficiency. 
While it may be true that a role for vitamin D deficiency 
may exist in some women, I think at best this is an over-
statement, and fails to consider the wealth of data to the 
contrary. If true, the authors' statement here would sug-
gest that vitamin D based therapy should be as efficaci-
ous as estrogen (or hormone) replacement therapy for 
postmenopausal osteoporosis, and there are numerous re-
ports in the literature that this is not the case. 
R.G. Erben: It should be mentioned that a dose of 1 
~g calcitriollday is already toxic in many patients with 
A. Caniggia and B. Frediani 
a higher calcium intake. The usual and also more phys-
iological treatment of nutritional osteomalacia is vitamin 
D and not calcitriol. Moreover, the risk of negative side 
effects is much lower with vitamin D treatment. 
Authors: Our own studies of postmenopausal osteopo-
rosis [5] have documented the fact that the administra-
tion of a physiological dose (1 p.g) of 1,25(0H)2vitD3 
corrects impaired intestinal transport of radio-calcium in 
ten days; this was not true for administration of 
24,25(0H)2vitD3. Since then, we have been studying 
the possible therapeutic benefits of calcitriol in post-
menopausal osteoporosis (more than 350 patients). We 
have found that: (a) the effective dose of calcitriol is 1 
p.g/day; (b) a dose of 0.5 p.g/day is not always suffi-
cient; and (c) a dose of 0.25 p.g/day is absolutely inef-
fective. Calcitriol treatment of postmenopausal osteo-
porosis is not a "vitamin D based therapy": vitamin D as 
such is absolutely ineffective in postmenopausal osteo-
porotic patients, as is borne out by the thousands of 
physicians who have been trying it over the last 50 years 
or more. No major adverse effects have been observed 
in 350 women, a number of whom have been followed 
for up to 14 years. The long-term administration of cal-
citriol underlines patient compliance, which is a good in-
dicator of treatment efficacy. These women have ob-
tained relief from pain and have rarely presented addi-
tional fractures; there have been no negative effects on 
renal function, and there is no malignant hypercalcemia 
provided calcium supplementation is forbidden . 
The medical treatment of osteomalacia can be per-
formed with vitamin D as such (because, in this patho-
logical condition, there is no defect in 1-alpha-hydroxila-
tion of vit. D). Of course, the calcitriol treatment is 
particularly efficient. 
R.G. Erben: The hypothesis that estrogens act directly 
on the !a-hydroxylase in the kidney is not correct for 
mammals (see e.g., Ash and Goldin, Am J Clin Nutr 
47: 694, or Reichel et al., N Engl J Med 320: 980). 
Please comment. 
Authors: As stated in the Discussion, the hypothesis 
that estrogens act directly on renal !a-hydroxylase has 
been supported by the studies of De Luca, Castillo and 
Tanaka [13, 14, 15] in hens. Studies of this kind are 
obviously more difficult in women, although opinions on 
the subject vary: Ash and Goldin did not agree in rats, 
Reichel et al. did not agree with the direct effects of 
estrogens on renal !a-hydroxylase. The positive effect 
of estrogens on intestinal radio-calcium absorption was 
demonstrated before the measurements of calcitriol 
levels [8]. The negative effects of ovariectomy have 
been documented by measurements of 1,25(0H)2vitD 
and the radio-calcium oral test [28). Gallagher et al. 
[17] indicated a significant decrease in 1,25(0H)2vitD 
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levels in postmenopausal osteoporotic women wlLich par-
allelled calcium malabsorption. In a recent pa1per de-
scribing an experimental study in women, Van JH:oof et 
al. [36] agree that estrogens stimulate 1a-hydrox.ylase in 
the kidney. 
W.S.S. Jee: What is the reason why the F()Qd and 
Drug Administration (FDA) bas not approved tb,e use of 
calcitriol in the treatment of osteoporosis? 
Authors: Calcitriol has been approved since a number 
of years in Italy, Switzerland, and New Zealandl, where 
it is currently on the market. 
W.S.S. Jee: In Japan, and possibly Europe, an:alogs of 
calcitriol are used in the treatment of osteoporo1sis. Do 
they differ in action from calcitriol? 
Authors: Calcitriol analogs can be used in the tr-eatment 
of postmenopausal osteoporosis provided they are 
hydroxylated in position 1. We have studied th~e effects 
of 1-a(OH)vitD3 in postmenopausal osteopomsis (121 
cases) [10]. It is less effective than 1,25(0H)2D3, 
probably because it needs previous hepatic hydmxylation 
in position 25. 
